Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cantaloupe (CTLP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cantaloupe (CTLP) over the last 16 years, with Q4 2025 value amounting to $53.0 million.

  • Cantaloupe's Cash & Equivalents rose 9140.86% to $53.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.0 million, marking a year-over-year increase of 9140.86%. This contributed to the annual value of $51.1 million for FY2025, which is 1319.42% down from last year.
  • As of Q4 2025, Cantaloupe's Cash & Equivalents stood at $53.0 million, which was up 9140.86% from $55.0 million recorded in Q3 2025.
  • Cantaloupe's Cash & Equivalents' 5-year high stood at $88.6 million during Q1 2021, with a 5-year trough of $27.7 million in Q4 2024.
  • Its 5-year average for Cash & Equivalents is $56.4 million, with a median of $52.1 million in 2025.
  • As far as peak fluctuations go, Cantaloupe's Cash & Equivalents skyrocketed by 24201.75% in 2021, and later plummeted by 6311.97% in 2022.
  • Quarter analysis of 5 years shows Cantaloupe's Cash & Equivalents stood at $76.3 million in 2021, then plummeted by 63.12% to $28.1 million in 2022, then soared by 54.49% to $43.5 million in 2023, then tumbled by 36.34% to $27.7 million in 2024, then soared by 91.41% to $53.0 million in 2025.
  • Its Cash & Equivalents stands at $53.0 million for Q4 2025, versus $55.0 million for Q3 2025 and $51.1 million for Q2 2025.